This Phase I/IIa clinical trial evaluated the safety and efficacy of subcutaneous injections of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in 34 adult patients with moderate-to-severe atopic dermatitis (AD). Participants were randomized to receive either a low dose (2.5 × 10⁷ cells) or a high dose (5.0 ×
